InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,408.42
(
-1.73%
)
US TECH 100
17,870.94
(
-3.09%
)
Dow Jones
40,345.41
(
-1.01%
)
Brent Oil
70.89
(
0.00%
)
Bitcoin
54,439.89
(
0.49%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

STOCK_GAINER6

Send PM Follow Ignore
Followers 22
Posts 2010
Boards Moderated 0
Alias Born 04/07/2011

STOCK_GAINER6

Re: piece o mind post# 36717

Monday, 10/21/2013 1:00:47 PM

Monday, October 21, 2013 1:00:47 PM

Post# of 80490
For AP26113 too soon to tell, AP26113 just live from expectations. And BTW, ALK inhibitor market is not the same as in Ponatinib's. But compared to the niche, in which imatinib is, ponantinib has more potential.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up